Multiple Myeloma

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

Marc S. Raab, MD, outlines the safety profile of teclistamab plus Dara-VRd in newly diagnosed multiple myeloma from the MajesTEC-5 trial.

Marc S. Raab, MD, discusses evaluating teclistamab–based induction regimens in patients with newly diagnosed multiple myeloma

Andrzej Jakubowiak, MD, PhD, discusses the design of the phase 3 ATLAS trial in patients with newly diagnosed multiple myeloma after ASCT.

Andrew Yee, MD, discusses data for a modified four-drug regimen studied in older patients with newly diagnosed multiple myeloma.

Marc S. Raab, MD, details the patient characteristics and design of the phase 2 MajesTEC-5 trial evaluating teclistamab in newly diagnosed multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

Andrzej Jakubowiak, MD, PhD, discusses how the data from the PERSEUS Study informed the ATLAS trial in multiple myeloma.

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.

Marc S. Raab, MD, discusses the rationale for assessing teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.